Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Steven Sun · SciRah

Researcher profile · Semantic Scholar

Steven Sun

Share profile

Steven Sun — researcher profile on SciRah

h-index: 20
Works: 59
Citations: 2,718

Most-cited papers

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
A. Younes, L. Sehn, P. Johnson, P. Zinzani +26 more
2019Journal of Clinical Oncology490 citations Open access
Semantic Scholar
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
M. Dreyling, W. Jurczak, M. Jerkeman, Rodrigo Santucci Silva +19 more
2016The Lancet443 citations Open access
Semantic Scholar
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
A. Gordon, M. Tonda, Steven Sun, W. Rackoff
2004Gynecologic Oncology425 citations
Semantic Scholar
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
A. Chanan-Khan, P. Cramer, F. Demirkan, G. Fraser +25 more
2016The Lancet Oncology407 citations
Semantic Scholar
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
J. San-Miguel, H. Avet-Loiseau, B. Paiva, Shaji K. Kumar +23 more
2021Blood109 citations Open access
Semantic Scholar
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA.
M. Cavo, J. San-Miguel, S. Usmani, K. Weisel +23 more
2021Blood98 citations Open access
Semantic Scholar
A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma.
T. Cooley, D. Henry, M. Tonda, Steven Sun +2 more
2007The Oncologist77 citations Open access
Semantic Scholar
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
H. Avet-Loiseau, J. San-Miguel, T. Casneuf, S. Iida +18 more
2021Journal of Clinical Oncology74 citations Open access
Semantic Scholar
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open‐label phase 3 study
Xiao-Jun Huang, L. Qiu, Jie Jin, Dao-Bin Zhou +19 more
2018Cancer Medicine49 citations Open access
Semantic Scholar
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
G. Fraser, A. Chanan-Khan, F. Demirkan, Rodrigo Santucci Silva +22 more
2020Leukemia and Lymphoma47 citations Open access
Semantic Scholar
Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies
U. Gayko, M. Fung, Fong Clow, Steven Sun +6 more
2015Annals of the New York Academy of Sciences42 citations Open access
Semantic Scholar
Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial
P. Johnson, S. Balasubramanian, B. Hodkinson, S. Shreeve +6 more
2023Blood Advances40 citations Open access
Semantic Scholar
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
J. San-Miguel, Avet-Loiseau, B. Paiva, Shaji K. Kumar +23 more
202237 citations
Semantic Scholar
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.
Jin Lu, W. Fu, Wei Li, Jian-Da Hu +16 more
2021Clinical Lymphoma, Myeloma & Leukemia35 citations Open access
Semantic Scholar
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.
R. Coleman, A. Gordon, J. Barter, Steven Sun +2 more
2007The Oncologist33 citations Open access
Semantic Scholar
Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials
P. Hillmen, G. Fraser, Jeffrey A. Jones, S. Rule +15 more
201532 citations
Semantic Scholar
Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials—Application of the Estimand Framework
E. Degtyarev, K. Rufibach, Shen-Tu Yue, Godwin Yung +9 more
2020Statistics in Biopharmaceutical Research31 citations Open access
Semantic Scholar
Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.
A. Chanan-Khan, P. Cramer, F. Demirkan, G. Fraser +16 more
2015Journal of Clinical Oncology24 citations
Semantic Scholar
A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)
A. Younes, L. Sehn, P. Johnson, P. Zinzani +15 more
2018Blood22 citations Open access
Semantic Scholar
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
M. Hallek, N. Kay, A. Osterborg, A. Chanan-Khan +6 more
2015Future Oncology21 citations Open access
Semantic Scholar
Estimands in hematologic oncology trials
Steven Sun, Hans-Jochen Weber, E. Butler, K. Rufibach +1 more
2020Pharmaceutical statistics16 citations Open access
Semantic Scholar
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib
S. Balasubramanian, Songbai Wang, C. Major, B. Hodkinson +11 more
2021British Journal of Haematology15 citations Open access
Semantic Scholar
A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).
A. Younes, P. Zinzani, L. Sehn, Peter W M Johnson +8 more
201415 citations
Semantic Scholar
Predictors of Efficacy and Health Resource Utilization in Treatment of Complicated Intra-abdominal Infections: Evidence for Pooled Clinical Studies Comparing Tigecycline with Imipenem–Cilastatin
R. Mallick, Steven Sun, S. Schell
2007Surgical Infections13 citations
Semantic Scholar
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial
G. A. Amos Burke, L. Vinti, E. Kabíčková, A. Beishuizen +16 more
2022Blood Advances11 citations Open access
Semantic Scholar
Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
Xiao-Yu Yan, X. Xu, K. Weisel, M. Mateos +10 more
2020Clinical and Translational Science11 citations Open access
Semantic Scholar
Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial
P. Johnson, S. Balasubramanian, B. Hodkinson, Michael Schaffer +8 more
2019Blood11 citations Open access
Semantic Scholar
A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia.
P. Pergola, G. Gartenberg, Min Fu, Steven Sun +2 more
2010American Society of Nephrology. Clinical Journal11 citations Open access
Semantic Scholar
Duration of and time to response in oncology clinical trials from the perspective of the estimand framework
Hans-Jochen Weber, S. Corson, Jiangya Li, François Mercier +5 more
2022Pharmaceutical statistics9 citations Open access
Semantic Scholar
The use of tricorticocancellous bone graft in severely comminuted intra-articular fractures of the distal radius.
R. Rogachefsky, E. Ouellette, Steven Sun, B. Applegate
2006Journal of Hand Surgery-American Volume9 citations
Semantic Scholar
Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial
Jun Zhu, X. Hong, Yu-Qin Song, B. Hodkinson +14 more
2022eJHaem8 citations Open access
Semantic Scholar
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial
C. Freeman, P. Pararajalingam, Ling Jin, S. Balasubramanian +14 more
2022Leukemia7 citations
Semantic Scholar
Cancer clinical trials – current and controversial issues in design and analysis
Steven Sun
2018Journal of Biopharmaceutical Statistics7 citations
Semantic Scholar
A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.
N. Fowler, W. Hiddemann, J. Leonard, J. Larsen +7 more
20147 citations
Semantic Scholar
Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -- Application of the Estimand Framework
E. Degtyarev, K. Rufibach, Shen-Tu Yue, Godwin Yung +9 more
20206 citations
Semantic Scholar
Design considerations in clinical trials with cure rate survival data: A case study in oncology
Steven Sun, Grace Liu, Tianmeng Lyu, Fu-Bo Xue +2 more
2018Pharmaceutical statistics6 citations
Semantic Scholar
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial
S. Balasubramanian, B. Hodkinson, S. Schuster, N. Fowler +9 more
2018Cancer Medicine5 citations Open access
Semantic Scholar
Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs
E. Balogh, A. Bindman, S. Eckhardt, S. Halabi +9 more
2019The Oncologist4 citations Open access
Semantic Scholar
Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)
S. Rule, W. Jurczak, M. Jerkeman, R. Santucci +19 more
20154 citations
Semantic Scholar
Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone
J. San-Miguel, H. Avet-Loiseau, B. Paiva, Shaji K. Kumar +22 more
2020Blood3 citations
Semantic Scholar
Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): safety analysis in the HELIOS trial
P. Cramer, A. Chanan-Khan, G. Fraser, F. Demirkan +18 more
20153 citations
Semantic Scholar
Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab
A. Chanan-Khan, P. Cramer, F. Demirkan, G. Fraser +18 more
20153 citations
Semantic Scholar
Sentinel Lymph Node Melanosis: A Report of Two Cases of Regressed Melanoma Metastases
Steven Sun, S. Peters, J. H. Howard
20172 citations Open access
Semantic Scholar
Early Changes in CA 125 After Treatment with Pegylated Liposomal Doxorubicin or Topotecan Do Not Always Reflect Best Response in Recurrent Ovarian Cancer Patients
R. Coleman, A. Gordon, J. Barter, Steven Sun +2 more
20062 citations
Semantic Scholar
Systemic Inflammatory Response and Fat Necrosis of Perineal Soft Tissues: A Rare Complication of Bladder-Drained Transplanted Pancreas Leak
Sara A. Mansfield, W. J. Melvin, Brent E Carlyle, Steven Sun +3 more
20161 citations Open access
Semantic Scholar
Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial
G. Fraser, A. Chanan-Khan, P. Cramer, F. Demirkan +18 more
20151 citations
Semantic Scholar
Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
P. Cramer, A. Chanan-Khan, G. Fraser, F. Demirkan +19 more
20151 citations
Semantic Scholar
Cytoreductive Stereotactic Body Radiotherapy with Tyrosine Kinase Inhibitors for Intrathoracic Oligoprogressive EGFR-mutated Lung Cancer
A. Rishi, Steven Sun, A. Karimi, A. Sim +6 more
20210 citations Open access
Semantic Scholar
Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor
Jin Lu, W. Fu, Wei Li, Jian-Da Hu +19 more
20200 citations
Semantic Scholar
894. Patient and Surgery Characteristics on Wound Complication and Surgical Site Infection in Sarcoma Patients undergoing Hemipelvectomy
J. Katzman, Steven Sun, D. Joyce, J. Greene
2020Open Forum Infectious Diseases0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Balasubramanian×12
Invite
S. Balasubramanian — researcher profile on SciRah
J. Vermeulen×12
Invite
J. Vermeulen — researcher profile on SciRah
A. Howes×11
Invite
A. Howes — researcher profile on SciRah
S. Rule×10
Invite
S. Rule — researcher profile on SciRah

×10

Invite

M. Salman — researcher profile on SciRah

A. Chanan-Khan×8

Invite

A. Chanan-Khan — researcher profile on SciRah

Invite

G. Fraser — researcher profile on SciRah

Invite

S. Grosicki — researcher profile on SciRah

Invite

M. Dilhuydy — researcher profile on SciRah

Invite

M. Mahler — researcher profile on SciRah

Invite

M. Hallek — researcher profile on SciRah

Invite

W. Wilson — researcher profile on SciRah